Welcome to Genafor − Open Services for Medical Research

AREVIR-GenaFor-Meeting 2017

Monitoring von resistenten HIV bei frisch infizierten und chronisch infizierten HIV-Patienten in Deutschland

When: 5. May - 6. May 2017 (9:00 am – 18:30 pm)

Where: Stadthotel am Römerturm, St. Apern-Str. 32, 50667 Köln

Registration is free like every year!


Claudia.Mueller@med.uni-duesseldorf.de for registration and accommodation

The meeting is an activity within the DZIF (www.dzif.de) , a translational research for infectious diseases. This meeting focusses on therapy optimization for HIV, HBV and HCV. While resistance testing is meanwhile „standard of care“ for HIV, and different projects such as AREVIR, RESINA, RKI Serokonverter-Analyse and the HIV-/HEP-MASTER project contributed already quite a remarkable time for better interpretation systems and analyzed the risk of transmission of resistant HIV in Germany, the DZIF activity within the TTU hepattis focusses on therapy optimization of HCV. On an European level the results of the mentioned projects are continuously integrated into the EUResist project together with the Karolinska and ARCA data and other European partners (www.euresist.org) . Our aim is the prediction of the most likely best working drug combinations. For that reason, geno2pheno (www.genafor.org) was developed. and is also freely available via internet. Nevertheless we need to understand the contribution of each resistance associated mutation and we have to agree on strategies for resistance testing and interpretation. These are the aims of HIV-GRADE (www.hiv-grade.de). New antiretroviral drugs in new classes require equivalent diagnostics. Within HIV-GRADE and geno2pheno such interpretation tools have been developed for HIV therapy optimization and are continuously updated. This includes the prediction of the coreceptor usage (tropism) prior to therapy with coreceptor blockers like maraviroc and resistance to the integrase inhibitors raltegravir, elvitegravir and dolutegravir. A workshop within the European project EucoHIV (www.eucohiv.org) for training and discussion on HIV-tropism is part of the meeting.

For HBV the technical expertise from the HIV-projects could be adapted, so that interpretation systems are already available. Geno2pheno and HIV-GRADE predict resistance, (sub-) genotype and escape mutants. New drugs seem to come and need probably new diagnostics which will be discussed on the meeting.

For HCV-therapy a new era has been entered with the availability of direct antiviral agents (DAAs). The DAAs are now established treatment options, they are extremely successful but also very expensive. Patient specific decisions are necessary and HCV therapy optimization within the DZIF-TTU hepatitis has the aim to optimize antiHCV-treatments with respect to the individual needs and with respect to cost effectiveness. geno2pheno[HCV] could be created in a cooperation off different groups including the DZIF sponsored centers Sarbrücken, Hannover, Köln, but also the university clinics Düsseldorf and partners within HIV-GRADE and partners from EURSIST.

A new topic for our meeting although an old challenge in immunocompromised patients is CMV. We will present and discuss the clinical situation, diagnostic tools and their application in therapeutic approaches.

Since 2000 the meeting is an exchange platform for clinicians, bioinformaticians and virologists. Participants have the chance to discuss clinical cases with other experts – the fasta file of the relevant case from HIV, HBV, HCV, CMV and clinical information is needed, while the interpretation systems can be utilized online at the meeting. The suppliers of the commercial systems will also be present. Furthermore, protocols are available at the meeting and will be visible on the internet after the meeting under www.genafor.org.

The language of the meeting is English.

The Meeting is kindly supported by:
Abbott ( €), Abbvie ( €), Cepheid ( €), Gilead (1.500,00 €), Hexal (800,00 €), Hologic (1.500,00 €), Janssen-Cilag GmbH (4.000,00 €), MSD Sharp & Dohme (1.500,00 €), QIAGEN (750,00 €) Roche ( €), Siemens-Healthcare (2.000,00 €), Vela (1.000,00 €), ViiV Healthcare (4.000,00 €)

The meeting will be certified from the Ärztekammer Nordrhein with credit points.
The Meeting is organised by genafor e.V.

Organising comittee:
Björn Jensen, Thomas Lengauer, Francesca Incardona, Heribert Knechten, Patrick Braun, Maurizio Zazzi, Mark Oette, Florian Klein, Rolf Kaiser and Claudia Müller